Compare Quest Diagnostics Inc (DGX) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fox Corp Class B — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Fox Corp Class B trades at $59.02 (market cap $24.97B). The key difference: Quest Diagnostics Inc and Fox Corp Class B are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.52%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Fox Corp Class B for 75 Days on average.
| DGX | FOX | |
|---|---|---|
Market Cap | $25.06B | $24.97B |
Volume | 927,361 | 643,221 |
Sector | Health | Media |
52-Week High | $247.45 | $67.76 |
52-Week Low | $173.49 | $44.39 |
Typical Hold Time | 56 Days | 75 Days |
Enterprise Value | $30.82B | $28.33B |
Dividend Yield | 1.52% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
FOX trades at $56.97, up 2.5% today, with a bearish technical signal but strong fundamentals including a P/E of 14.59 and net income margin of 9.84%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while cash flow improved to $1.03B in 2025. The stock faces resistance near $57 with support at $55.
The outlook is mixed: analyst consensus targets $84.75 (49% upside) with 42% buy ratings, but technical indicators and projected 2026 earnings decline pose risks. Key opportunities include valuation discount and dividend yield; risks involve earnings volatility and competitive pressures in media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
